NASDAQ · SAVA
Healthcare · Biotechnology
$2.38
Up+$0.03 (+2.33%)
Updated Sep 16, 2026, 12:03 PM
SID Score
4.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
SAVA does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning SAVA.
SAVA research
Company profile and research snapshot.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 6, 2025 | LUCID CAPITAL MARKETS | Buy | — |
| Mar 25, 2025 | HC Wainwright & Co. | Neutral | — |
| Mar 4, 2025 | HC Wainwright & Co. | Neutral | — |
| Nov 26, 2024 | HC Wainwright & Co. | Neutral | — |
| Nov 8, 2024 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Mar 10, 2026
Cassava Sciences, Inc. (NASDAQ: SAVA) today announced the rebranding of the Company, with a name change to Filana Therapeutics, Inc. ("Filana Therapeutics", or the "Company"). The new name and corporate brand
Benzinga · Feb 19, 2026
Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company"))), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis
Yahoo · Jan 28, 2026
Cassava Technologies, a global technology leader of African heritage and AXON Networks (AXON), a global leader in intelligent network platforms, today announced a strategic partnership to co-develop, deploy, and manage Africa's first end-to-end Operator-as-a-Service (OaaS) platform.
Yahoo · Jan 13, 2026
As previously disclosed, the studies did not meet pre-specified co-primary, secondary, or exploratory biomarker endpoints The paper provides a detailed analysis of the RETHINK-ALZ and REFOCUS-ALZ studies and confirms simufilam’s favorable safety profile in these studies Exploratory post-hoc analyses offer informative insights AUSTIN, Texas, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, inves
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SAVA.
